These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7707101)

  • 1. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.
    Perez EA
    J Clin Oncol; 1995 Apr; 13(4):1036-43. PubMed ID: 7707101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
    Jordan K; Hinke A; Grothey A; Voigt W; Arnold D; Wolf HH; Schmoll HJ
    Support Care Cancer; 2007 Sep; 15(9):1023-33. PubMed ID: 17205281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
    Morrow GR; Hickok JT; Rosenthal SN
    Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
    Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
    Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
    Yarker YE; McTavish D
    Drugs; 1994 Nov; 48(5):761-93. PubMed ID: 7530631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
    Abali H; Celik I
    Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
    Barrajon E; de las Peñas R
    Support Care Cancer; 2000 Jul; 8(4):323-33. PubMed ID: 10923774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there differences among the serotonin antagonists?
    Tonato M; Roila F; Del Favero A
    Support Care Cancer; 1994 Sep; 2(5):293-6. PubMed ID: 8000725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study.
    Yalçin S; Tekuzman G; Baltali E; Ozişik Y; Barişta I
    Am J Clin Oncol; 1999 Feb; 22(1):94-6. PubMed ID: 10025391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
    Oge A; Alkiş N; Oge O; Kartum A
    J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis.
    Jordan K; Hinke A; Grothey A; Schmoll HJ
    Support Care Cancer; 2005 Jan; 13(1):26-31. PubMed ID: 15668744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Simpson K; Spencer CM; McClellan KJ
    Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.
    Perez EA
    Drug Saf; 1998 Jan; 18(1):43-56. PubMed ID: 9466087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.